HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar reiterated a Buy rating on Acrivon Therapeutics (NASDAQ:ACRV) and maintained a $20 price target.
April 25, 2024 | 11:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Acrivon Therapeutics maintains a Buy rating and a $20 price target from HC Wainwright & Co., indicating a positive outlook.
The reiteration of a Buy rating and a maintained price target of $20 by a reputable analyst firm like HC Wainwright & Co. suggests a strong confidence in Acrivon Therapeutics' potential for growth. This endorsement is likely to positively influence investor sentiment and could lead to an uptick in ACRV's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100